教授、主任医师、博士生导师                       

联系方式

电邮: zhangguojun@kmmu.edu.cn

地址: 中国云南省昆明市西山区昆州路号

当前职位

昆明医科大学第三附属医院 院长

北京大学肿瘤医院云南医院 执行院长

云南省肿瘤医院 执行院长

福建省乳腺癌精准诊治重点实验室 主任

厦门市内分泌肿瘤精准诊治重点实验室 主任

厦门市乳甲肿瘤临床医学研究中心 主任

教育经历

1995.04 - 1999.03  日本福岛县立医科大学，医学博士（外科学）

1990.09 - 1995.12  中国医科大学，医学博士（外科学）

1981.09 - 1987.07  中国医科大学，医学学士（临床医学）

工作经历

2023.08至今 昆明医科大学第三附属医院，院长

2023.01- 2023.07 厦门大学附属翔安医院，乳甲外科主任

2017.05 - 2022.12 厦门大学附属翔安医院，执行院长

2008.08 - 2017.04 汕头大学医学院附属肿瘤医院，院长；乳腺中心，主任

2005.01 - 2008.07 美国Merck & Co.公司研究实验室，高级科学家

1999.08 - 2004.12 美国Harvard Medical School/Dana-Farber癌症研究所， 医学研究所，博士后研究员，福岛医科大学，研究员

1993.05 - 1995.03 日本国立癌症中心，研修

1987.07 - 1993.04 中国医科大学附属第一医院普外三科，历任住院医师、主治医师、讲师

荣誉称号

长江学者奖励计划特聘教授

国家特支计划（万人计划）领军人才

享受国务院政府特殊津贴

新世纪百千万人才工程国家级人选

福建省引进高层次人才A类和百人计划创新人才

广东省特支计划杰出人才

厦门市高层次卫生领军人才和双百计划创新人才

社会兼职

中国抗癌协会常务理事

云南省抗癌协会理事长

国家肿瘤防治专家委员会 委员

中国抗癌协会第十届乳腺癌专业委员会 副主任委员

《中华医学杂志》第二十九届 编辑委员会编辑委员

中国医师协会肿瘤医师分会第二届委员会 常务委员

中国抗癌协会国际医疗交流分会 副主任委员

中国研究型医院学会环境医学分会 副会长

福建省医学会乳腺病学分会 副主任委员

厦门市医学会第八届理事会 副会长

厦门医师协会乳腺病学分会 主任委员

《Molecular Imaging & Biology》高级编委

《American Journal of Nuclear Medicine and Molecular Imaging》高级编委

学术成就

醉心于乳腺癌基础和应用研究近30年，在国内独树一帜建立了以光学分子影像技术为中心的乳腺癌精准诊治技术体系。

1、精准外科：率先将新型荧光染料吲哚菁绿（ICG）应用于乳腺癌前哨淋巴结活检，并结合其它材料拓展到保乳手术安全切缘评估，建立了国内首个分子影像手术导航软硬件支撑平台，大大降低了盲目腋窝清扫率、提高了保乳率。

2、疗效评估：另辟蹊径构建了不同于常规机制的细胞周期抗癌药物靶点CDK活性监测体系，丰富了抗肿瘤治疗实时疗效评价方法，有助于及时调整优化乳腺癌治疗方案。

3、新型靶点：首次确定了Notch3分子在管腔型乳腺癌中的抑癌角色及其上下游传导通路，为乳腺癌靶向药物研发和靶向治疗提供了新的潜在靶点。

主持973课题、国家自然科学基金重大研究计划、国家自然科学基金重点国际（地区）合作项目等十余项国家级和省级课题，总资助金额万以上；发表高质量期刊论著百余篇，获各级科技奖项、中国发明专利项。已培养硕博士研究生和博士后七十余名。

科研项目

论文

（*并列第一作者，^#通讯作者或并列通讯作者）

1. 2. ****##3. *##Ⅱ 4. **#5. *##6. **## 7.  ***## 8. Niu L*, Lou KL*, Zhu Z*, Liu WZ*, Gao WL, Hu GY, Gao JX, Zhang GJ^#, Huang WH^#Aptamer-based NIR II imaging for breast cancer surgical resection Npj Imaging 2025 Aug 19;3(1):38.

9. Rong Guo, Xiting Wang, Yinju Yang, Jiaying Zou, Ming Li, Zeying Li, Yuan Yan, Nan Lan, JianYun Nie^#, Yiyin Tang^#, Guojun Zhang^#rognostic value of a lncRNA signature in early-stage invasive breast cancer patients10.  –11. ###12. ** ###≤ EClinicalMedicine13. ，，，，，，，，#，#14. , Jing-Wen Bai, Sen Jiang, Zhen-Hui Li, Jie-Zhou He, Zhi-Cheng Du, Xue-Qi Fan, Shao-Zi Li, Guo-Jun Zhang^#, predicting positive margins in breast-conserving surgery: a multi-center study 15. Chen WL*, Zhang YQ*, Zhang LX*, Luo YX, Yang X, Zhu YY, Wang GM, Huang WH, Zhang DL, Zeng YZ, Ronghui Li, Guo CP, Wang JZ, Zhao W, Liu N, Zhang GJ^#. Intraoperative evaluation of tumor margins using a TROP2 near-infrared imaging probe to enable human breast-conserving surgery, Science Translational Medicine, 2024 Oct 16.

16. Ming ZH*, Zhang YQ*, Song L, Chen M, Lin LL, He YY, Liu WL, Zhu YY, Zhang Y, Zhang GJ^#. Rare Earth Nanoprobes for Targeted Delineation of Triple Negative Breast Cancer and Enhancement of Radioimmunotherapy. Advanced Science, 2024 May 22.

17. Dang YY*, Bai JW*, Lou KL, Yang RQ, Gao YY, Tian HA, Li JQ, Lin LL, Lv CR, Wang PY^#, Zhang GJ^#. Intraoperative Surgical Margin Assessment by NIR-II Imaging with Urine Excretable Nd-Based Nanoprobe in Breast Cancers. Adv. Funct. Mater. 2024, https://doi.org/10.1002/adfm.202311673.18. Li JW*, Deng QM*, Zhu JL, Wei M, Hu XY, Chen HY, Luo Z, Lin LL, Wei XL, Zhang YQ, Lou KL, Gao YY, Zhang GJ, Bai JW^#. Methylation of ESR1 promoter induced by SNAI2–DNMT3B complex promotes epithelial–mesenchymal transition and correlates with poor prognosis in ERα-positive breast cancers. MedComm, 2023 Oct 24;4(6): e403.

19. Liu WL*, Zhang YQ*, Luo XY, Zhu YY, Song L, Ming ZH, Zhang LX, Li MI, Rui-Chan Lv, Zhang GJ^#, Chen M^#. Novel Dual-Mode NIR-II/MRI Nanoprobe Targeting PD-L1 Accurately Evaluates the Efficacy of Immunotherapy for Triple-Negative Breast Cancer. Int J Nanomedicine. 2023 Sep 8:18:5141-5157.

20. Lin B, Dai RY, Liu ZH, Li WJ, Bai JW, Zhang GJ^#, Lv RC^#. Dual-targeting lanthanide-ICG-MOF nanoplatform for cancer Theranostics: NIR II luminescence imaging guided sentinel lymph nodes surgical navigation. J Photochem Photobiol B. 2023 Aug; 245:112731.

21. Zhu YY*, Song L*, Zhang YQ, Liu WL, Chen WL, Gao WL, Zhang LX, Wang JZ, Ming ZH, Zhang Y^#, Zhang GJ^#. Development of a rare earth nanoprobe enables in vivo real-time detection of sentinel lymph node metastasis of breast cancer using NIR-IIb imaging. Cancer Res. 2023 Aug 4: CAN-22-3432.

22. Qi YZ, Li MF, Li SZ, Zeng D, Xiao YS, Li JW, Ye QQ, Bremer E, Zhang GJ^#. Notch1 promotes resistance to cisplatin by up-regulating Ecto-5'-nucleotidase (CD73) in triple-negative breast cancer cells. Cell Death Discovery. 2023 Jun 30;9(1):204.

23. Wei M, Bai JW, Shen X, Lou KL, Gao YY, Lv RC, Wang PY^#, Liu XL^#, Zhang GJ^#. Glutathione-Exhausting Nanoprobes for NIR-II Fluorescence Imaging-Guided Surgery and Boosting Radiation Therapy Efficacy via Ferroptosis in Breast Cancer. ACS Nano. 2023 Jun 27;17(12):11345-11361.

24. Zhang YQ*, Liu WL*, Luo XJ, Shi JP, Zeng YZ, Chen WL, Huang WH, Zhu YY, Gao WL, Li RH, Ming ZH, Zhang LX, Yang RQ, Wang JZ, Zhang GJ^#. Novel Self-Assembled Multifunctional Nanoprobes for Second-Near-Infrared-Fluorescence-Image-Guided Breast Cancer Surgery and Enhanced Radiotherapy Efficacy. Adv Sci (Weinh). 2023 Apr;10(10): e2205294.

25. Zhao X*, Bai JW*, Guo Q, Ren K^#, Zhang GJ^#. Clinical applications of deep learning in breast MRI. Biochim Biophys Acta Rev Cancer. 2023 Mar;1878(2):188864.

26. Bai JW*, Qiu SQ*, Zhang GJ^#. Molecular and functional imaging in cancer-targeted therapy: current applications and future directions. Signal Transduct Target Ther. 2023 Feb 27;8(1):89.

27. Chen WL*, Wang GM*, Zhang GJ^#. Insights into the transition of ductal carcinoma in situ to invasive ductal carcinoma: morphology, molecular portraits, and the tumor microenvironment. Cancer Biol Med. 2022 Nov 1;19(10):1487–95.

28. Chen WL*, Zhang YQ*, Li RH, Huang WH, Wei XL, Zeng D, Liang YK, Zeng YZ, Chen M, Zhang LX, Gao WL, Zhu YY, Li YC^#, Zhang GJ^#. Notch3 Transactivates Glycogen Synthase Kinase-3-Beta and Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer Cells. Cells. 2022 Sep 14;11(18):2872.

29. Liang YK, Voshart D, Paridaen JTML, Oosterhof N, Liang D, Thiruvalluvan A, Zuhorn IS, den Dunnen WFA, Zhang GJ, Lin HY, Barazzuol L, Kruyt FAE^#. CD146 increases stemness and aggressiveness in glioblastoma and activates YAP signaling. Cell Mol Life Sci. 2022 Jul 5;79(8):398.

30. Liu WL*, Zhang YQ*, Li LT, Zhu YY, Ming ZH, Chen WL, Yang RQ, Li RH, Chen M^#, Zhang GJ^#. Application of molecular imaging in immune checkpoints therapy: From response assessment to prognosis prediction. Crit Rev Oncol Hematol. 2022 Jun 22; 176:103746.

31. Li JW, Wu J, Long QY, Wu YA, Hu XY, He YK, Jiang MZ, Li J, Zhao LL, Yang SQ, Chen XY, Wang MH, Zheng JS, Wu FF, Wu RL, Ren LL, Bu L, Wang HZ, Li K, Fu LJ, Zhang GJ^#, Zheng YL^#,Gao ZC^#. Comprehensive Humoral and Cellular Immune Responses to SARS-CoV-2 Variants in Diverse Chinese Population. Research (Wash D C). 2022 Jun 16; 2022:9873831.

32. Gao YY*, Yang RQ*, Lou KL, Dang YY, Dong YY, He YY, Huang WH, Chen M, Zhang GJ^#. In vivo visualization of fluorescence reflecting CDK4 activity in a breast cancer mouse model. MedComm (2020). 2022 Jun 10;3(3): e136.

33. Lou KL*, Wang PY*, Yang RQ, Gao YY, Tian HN, Dang YY, Li Y, Huang WH, Min-Chen, Liu XL^#, Zhang GJ^#. Fabrication of tumor targeting rare-earth nanocrystals for real-time NIR-IIb fluorescence imaging-guided breast cancer precise surgery. Nanomedicine. 2022 Apr 4:102555.

34. Yang RQ*, Chen M*, Zhang Q, Gao YY, Lou KL, Lin TT, Huang WH, Zeng YZ, Zhang YQ, Dang YY, Ren L^#, Zhang GJ^#. Development and Preclinical Evaluation of a Near-Infrared Fluorescence Probe Based on Tailored Hepatitis B Core Particles for Imaging-Guided Surgery in Breast Cancer. International Journal of Nanomedicine. 2022 Mar 22; 17:1343-1360.

35. Yang RQ*, Wang PY*, Lou KL, Dang YY, Tian HN, Li Y, Gao YY, Huang WH, Zhang YQ, Liu XL^#, Zhang GJ^#. Biodegradable Nanoprobe for NIR-II Fluorescence Image-Guided Surgery and Enhanced Breast Cancer Radiotherapy Efficacy. Advance Science. 2022 Feb 16: e2104728.

36. Liu JJ*, Wang Z*, Nie LM, Zhu YY, Li G, Lin LL, Chen M^#, Zhang GJ^#. RGD-functionalised melanin nanoparticles for intraoperative photoacoustic imaging-guided breast cancer surgery. European Journal Nuclear Medicine and Molecular Imaging. 2022 Feb;49(3):847-860.

37. Ouyang YX*, Feng J*, Wang Z, Zhang GJ^#, Chen M^#. miR-221/222 sponge abrogates tamoxifen resistance in ER-positive breast cancer cells through restoring the expression of ERα. Mol Biomed. 2021 Jun 30;2(1):20.

38. Zhang YQ, Zhang F, Zeng YZ, Chen M, Huang WH, Wu JD, Chen WL, Gao WL, Bai JW, Yang RQ, Zeng HC, Wei XL^#, Zhang GJ^#. Mutant p53 and Twist1 Co-expression Predicts Poor Prognosis and Is an Independent Prognostic Factor in Breast Cancer. Frontiers in Oncology. 2021 Jun 24; 11:628814.

39. Zhang YQ, Liang YK, Wu Y, Chen M, Chen WL, Li RH, Zeng YZ, Huang WH, Wu JD, Zeng D, Gao WL, Chen CF, Lin HY, Yang RQ, Zhu JW, Liu WL, Bai JW, Wei M, Wei XL^#, Zhang GJ^#. Notch3 inhibits cell proliferation and tumorigenesis and predicts better prognosis in breast cancer through transactivating PTEN. Cell Death & Disease. 2021 May 18;12(6):502.

40. Yang RQ*, Lou KL*, Wang PY, Gao YY, Zhang YQ, Chen M, Huang WH, Zhang GJ^#. Surgical Navigation for Malignancies Guided by Near-Infrared-II Fluorescence Imaging. Small Methods. 2021 Mar;5(3): e2001066.

41. Wang Z, Chen M, Liu JJ, Chen RH, Yu Q, Wang GM, Nie LM^#, Huang WH^#, Zhang GJ^#. Human Serum Albumin Decorated Indocyanine Green Improves Fluorescence-Guided Resection of Residual Lesions of Breast Cancer in Mice. Frontiers in Oncology. 2021 Mar 8; 11:614050.

42. Guo CP*, Guo YX*, Liu JJ, Gao YY, Wei M, Zhao RJ, Chen M^#, Zhang GJ^#. The G1 phase optical reporter serves as a sensor of CDK4/6 inhibition in vivo. International Journal of Biological Sciences. 2021 Jan 31;17(3):728-741.

43. Wei M*, Bai JW*, Niu L, Zhang YQ, Chen HY, Zhang GJ^#. The Complex Roles and Therapeutic Implications of m (6)A Modifications in Breast Cancer. Frontiers in cell and developmental biology. 2021 Jan 11; 8:615071.

44. Wu Y, Yuan MH, Wu HT, Chen WJ, Zhang ML, Ye QQ, Liu J^#, Zhang GJ^#. MicroRNA-488 inhibits proliferation and motility of tumor cells via downregulating FSCN1, modulated by Notch3 in breast carcinomas. Cell Death & Disease. 2020 Oct 24;11(10):912.

45. Wu JD*, Wang Z*, Zeng HC, He LF, Zhang YQ, Huang GS, Zhang F, Wei XL, Huang WH, Zhang GJ^#. Comparison of indocyanine green and methylene blue use for axillary reverse mapping during axillary lymphnode dissection. MedComm. 2020 Sep 17;1(2):211-218.

46. Fang CB, Wu HT, Zhang ML, Liu J^#, Zhang GJ^#. Fanconi anemia pathway: mechanisms of breast cancer predisposition development and potential therapeutic targets. Frontiers in Cell and Developmental Biology. 2020 Apr 2; 8:160.

47. Bai JW*, Wei M*, Li JW, Zhang GJ^#. Notch signaling pathway and endocrine resistance in breast cancer. Frontiers in Pharmacology. 2020 Jun 19; 11:924.

48. Zhang YQ, Chen WL, Zhang F, Wei XL, Zeng D, Liang YK, Wu JD, Zhang LY, Guo CP, Zeng HC, Hao SS, Li RH, Huang WH^#, Zhang GJ^#. Over expression of both VEGF C and twist predicts poor prognosis in human breast cancer. Clinical and Translational Oncology. 2019 Sep;21(9):1250-1259.

49. Li MF, Qi YZ, Chen M, Wang Z, Zeng D, Xiao YS, Li SZ, Lin HY, Wei XL, Zhang GJ^#. GATA binding protein 3 boosts extracellular ATP hydrolysis and inhibits metastasis of breast cancer by up-regulating ectonucleoside triphosphate diphosphohydrolase 3. International Journal of Biological Sciences. 2019 Sep 7;15(12):2522-2537.

50. Chen CF, Zhang YL, Huang ZY, Wu JD, Huang WH^#, Zhang GJ^#. Decrease in the Ki67 index during neoadjuvant chemotherapy predicts favorable relapse-free survival in patients with locally advanced breast cancer. Cancer Biology & Medicine. 2019 Aug;16(3):575-586.

51. Zeng HC, Hu JL, Bai JW, Zhang GJ^#. Detection of sentinel lymph nodes with near-infrared imaging in malignancies. Molecular Imaging and Biology. 2019 Apr;21(2):219-227.

52. Xu JZ*^#, Shao CC*, Wang XJ, Zhao X, Chen JQ, Ouyang YX, Feng J, Zhang F, Huang WH, Ying Q, Chen CF, Wei XL, Dong HY, Zhang GJ^#, Chen M^#. circTADA2As suppress breast cancer progression and metastasis via targeting miR-203a-3p/SOCS3 axis. Cell Death & Disease. 2019 Feb 20;10(3):175.

53. Xiao YS, Zeng D, Liang YK, Wu Y, Li MF, Qi YZ, Wei XL, Huang WH, Chen M, Zhang GJ^#. Major vault protein is a direct target of Notch1 signaling and contributes to chemoresistance in triple-negative breast cancer cells. Cancer Letters. 2019 Jan;440-441:156-167.

54. Shen JX, Liu J^#, Zhang GJ^#. Interleukin-33 in malignancies: friends or foes? Frontiers in Immunology. 2018 Dec 20; 9:3051.

55. Li RH, Chen M, Liu J, Shao CC, Guo CP, Wei XL, Li YC, Huang WH, Zhang GJ^#. Long noncoding RNA ATB promotes the epithelial-mesenchymal transition by upregulating the miR-200c/Twist1 axe and predicts poor prognosis in breast cancer. Cell Death & Disease. 2018 Dec 5;9(12):1171.

56. Wen XF*, Chen M*, Wu Y, Chen MN, Glogowska A, Klonisch T^#, Zhang GJ^#. Inhibitor of DNA binding 2 inhibits epithelial-mesenchymal transition via up-regulation of Notch3 in breast cancer. Translational Oncology. 2018 Oct;11(5):1259-1270.

57. Liu J, Shen JX, He, Zhang GJ^#. Bioluminescence imaging for monitoring miR-200c expression in breast cancer cells and its effects on epithelial-mesenchymal transition progress in living animals. Molecular Imaging and Biology. 2018 Oct;20(5):761-770.

58. Wu JD*, Hong CQ*, Huang WH, Wei XL, Zhang F, Zhuang YX, Zhang YQ, Zhang GJ^#. L1 Cell Adhesion Molecule and Its Soluble Form sL1 Exhibit Poor Prognosis in Primary Breast Cancer Patients. Clinical Breast Cancer. 2018 Oct;18(5): e851-e861.

59. Lin HY, Liang YK, Dou XW, Chen CF, Wei XL, Zeng, Bai JW, Guo YX, Lin FF, Huang WH, Du CW, Li YC, Chen M^#, Zhang GJ^#. Notch3 inhibits epithelial-mesenchymal transition in breast cancer via a novel mechanism, upregulation of GATA-3 expression. Oncogenesis. 2018 Aug 13;7(8):59.

60. Liang YK*, Lin HY*, Dou XW, Chen M, Wei XL, Zhang YQ, Wu Y, Chen CF, Bai JW, Xiao YS, Qi YZ, Kruyt FAE, Zhang GJ^#. MiR-221/222 promote epithelial-mesenchymal transition by targeting Notch3 in breast cancer cell lines. NPJ Breast Cancer. 2018 Aug 6; 4:20.

61. Wang JW*, Wei XL*, Dou XW, Huang WH, Du CW, Zhang GJ^#. The association between Notch4 expression, and clinicopathological characteristics and clinical outcomes in patients with breast cancer. Oncology Letters. 2018 Jun;15(6):8749-8755.

62. Liu J, Shen JX, Wu HT, Li XL, Wen XF, Du CW, Zhang GJ^#. Collagen 1A1 (COL1A1) promotes metastasis of breast cancer and is a potential therapeutic target. Discovery Medicine. 2018 May;25(139):211-223.

63. Bai JW, Li YC, Zhang GJ^#. Cell cycle regulation and anticancer drug discovery. Cancer Biology & Medicine. 2017 Nov;14(4):348-362.

64. Dou XW*, Liang YK*, Lin HY, Wei XL, Zhang YQ, Bai JW, Chen CF, Chen M, Du CW, Li YC, Tian J, Man K, Zhang GJ^#. Notch3 Maintains Luminal Phenotype and Suppresses Tumorigenesis and Metastasis of Breast Cancer via Trans-Activating Estrogen Receptor-α. Theranostics. 2017 Sep 20;7(16):4041-4056.

65. Bai JW, Zhang YQ, Li YC, Zhang GJ^#. Analysis of Epithelial-Mesenchymal Transition Induced by Overexpression of Twist. Methods in Molecular Biology. 2017 Aug 9; 1652:259-274.

66. Bai JW, Chen MN, Wei XL, Li YC, Lin HY, Chen M, Li JW, Du CW, Man K, Zhang GJ^#. The zinc-finger transcriptional factor slug transcriptionally down-regulates ERα by recruiting lysine-specific demethylase 1 in human breast cancer. Oncogenesis. 2017 May 8;6(5): e330.

67. He LF*, Xu HW*, Chen M, Xian ZR, Wen XF, Chen MN, Du CW, Huang WH, Wu JD, Zhang GJ^#. Activated-PAK4 predicts worse prognosis in breast cancer and promotes tumorigenesis through activation of PI3K/AKT signaling. Oncotarget. 2017 Mar 14;8(11):17573-17585.

68. Liang YK*, Zeng D*, Xiao YS, Wu Y, Ouyang YX, Chen M, Li YC, Lin HY, Wei XL, Zhang YQ, Kruyt FAE^#, Zhang GJ^#. MCAM/CD146 promotes tamoxifen resistance in breast cancer cells through induction of epithelial-mesenchymal transition, decreased ERα expression and AKT activation. Cancer Letters. 2017 Feb 1;386: 65-76.

69. He KS*, Chi CW*, Kou DQ*, Huang WH, Wu JD, Wang YB, He LF, Ye JZ, Mao YM, Zhang GJ^#, Wang JD^#, Tian J^#. Comparison between the indocyanine green fluorescence and blue dye methods for sentinel lymph node biopsy using novel fluorescence image-guided resection equipment in different types of hospitals. Translational Research. 2016 Dec; 178:74-80.

70. Zhang XX, Liu X, Luo J, Xiao W, Ye X, Chen M, Li YC^#, Zhang GJ^#. Notch3 inhibits epithelial-mesenchymal transition by activating Kibra-mediated Hippo/YAP signaling in breast cancer epithelial cells. Oncogenesis. 2016 Nov 14;5(11): e269.

71. Liu J*, Shen JX*, Wen XF, Guo YX, Zhang GJ^#. Targeting Notch degradation system provides promise for breast cancer therapeutics. Critical Reviews in Oncology/Hematology. 2016 Aug; 104:21-9.

72. Wu JD, Huang WH, Qiu SQ, He LF, Guo CP, Zhang YQ, Zhang F, Zhang GJ^#. Breast reconstruction with single-pedicle TRAM flap in breast cancer patients with low midline abdominal scar. Scientific Reports. 2016 Jul 13; 6:29580.

73. Qiu SQ*, Zeng HC*, Zhang F, Chen C, Huang WH, Pleijhuis RG, Wu JD, van Dam GM, Zhang GJ^#. A nomogram to predict the probability of axillary lymph node metastasis in early breast cancer patients with positive axillary ultrasound. Scientific Reports. 2016 Feb 15; 6:21196.

74. Chen CF, Dou XW, Liang YK, Lin HY, Bai JW, Zhang XX, Wei XL, Li YC, Zhang GJ^#. Notch3 overexpression causes arrest of cell cycle progression by inducing Cdh1 expression in human breast cancer cells. Cell Cycle. 2016;15(3):432-40.

75. Wei XL, Dou XW, Bai JW, Luo XR, Qiu SQ, Xi DD, Huang WH, Du CW, Man K, Zhang GJ^#. ERα inhibits epithelial-mesenchymal transition by suppressing Bmi1 in breast cancer. Oncotarget. 2015 Aug 28;6(25):21704-17.

76. Zhang YQ*, Wei XL*, Liang YK, Chen WL, Zhang F, Bai JW, Qiu SQ, Du CW, Huang WH^#, Zhang GJ^#. Over-expressed twist associates with markers of epithelial mesenchymal transition and predicts poor prognosis in breast cancers via ERK and Akt activation. PLoS One. 2015 Aug 21;10(8): e0135851.

77. Li YK^#, Zheng Y, Lin JB, Xu GX, Cai AQ, Zhou XG, Zhang GJ^#. CT imaging of ovarian yolk sac tumor with emphasis on differential diagnosis. Scientific Reports. 2015 Jun 15;5: 11000.

78. He DE, Bai JW, Liu J, DU CW, Huang WH^#, Zhang GJ^#. Clinicopathological characteristics and prognosis of breast cancer patients with type 2 diabetes mellitus. Molecular and Clinical Oncology. 2015 May;3(3):607-612.

79. Fu XJ*, Shi XJ*, Lin K, Lin H, Huang WH, Zhang GJ^#, Au WW^#. Environmental and DNA repair risk factors for breast cancer in south China. International Journal of Hygiene and Environmental Health. 2015 May;218(3):313-8.

80. Wei XL, Chen CF, Xi DD, Bai JW, Huang WH, Luo LX, Wu MY, Zhang GJ^#. A case of primary neuroendocrine breast carcinoma that responded to neo-adjuvant chemotherapy. Frontiers of Medicine. 2015 Mar;9(1):112-6.

81. Liang SX*, Peng X*, Li XL, Yang P, Xie LH, Li YC, Du CW^#, Zhang GJ^#. Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin. Oncotarget. 2015 Jan 20;6(2):1020-30.

82. Wei XL, Zhang DH^#, Dou XW, Niu N, Bai JW, Huang WH, Zhang GJ^#. Elevated 14, 15- epoxyeicosatrienoic acid by increasing of cytochrome P450 2C8, 2C9 and 2J2 and decreasing of soluble epoxide hydrolase associated with aggressiveness of human breast cancer. BMC Cancer. 2014 Nov 18; 14:841.

83. Huang WH, Qiu SQ, Wu JD, Du CW, Cui YK, Zhang GJ^#. Analysis of clinicopathological characteristics and prognosis of 1425 primary breast cancer patients in eastern Guangdong, China. Current Signal Transduction Therapy. 2014 Nov 14; 9(1): 44-9.

84. Wei JT, Huang WH, Du CW, QIU SQ, Wei XL, Liu J, Zhang GJ^#. Clinicopathological features and prognostic factors of young breast cancers in eastern Guangdong of China. Scientific Reports. 2014 Jun 19; 4:5360.

85. Liu J*, Shen JX*, Hu JL, Huang WH, Zhang GJ^#. Significance of interleukin-33 and its related cytokines in patients with breast cancers. Frontiers in Immunology. 2014 Apr 7;5: 141.

86. Yang P, Liang SX, Huang WH, Zhang HW, Li XL, Xie LH, Du CW^#, Zhang GJ^#. Aberrant expression of CXCR4 significantly contributes to metastasis and predicts poor clinical outcome in breast cancer. Current Molecular Medicine. 2014 Jan;14(1):174-84.

87. Chi CW, Ye JZ, Ding HL, He D, Huang WH, Zhang GJ^#, Tian J^#. Use of indocyanine green for detecting the sentinel lymph node in breast cancer patients: From preclinical evaluation to clinical validation. PLoS one. 2013 Dec 16;8(12): e83927.

88. Wu JD, Huang WH, Huang ZY, Chen M, Zhang GJ^#. Brachial plexus palsy after a left-side modified radical mastectomy with immediate latissimusdorsi flap reconstruction: report of a case. World Journal of Surgical Oncology. 2013 Oct 15; 11:276.

89. Chen SF, Du CW^#, Yang P, Zhang HW, Man K, Zhang GJ^#. The molecular and clinicopathologic characteristics of bilateral breast cancer. Scientific Reports. 2013; 3:2590.

90. Qiu SQ, Wei XL, Huang WH, Wu MY, Qin YS, Li YK, Zhang GJ^#. Diagnostic and therapeutic strategy and the most efficient prognostic factors of breast malignant fibrous histiocytoma. Scientific Reports. 2013; 3:2529.

91. Yang P, Du CW^#, Man K, Liang SX, Zhang GJ^#. The impact of p53 in predicting clinical outcome of breast cancer patients with visceral metastasis. Scientific Reports. 2013; 3:2246.

92. Zhang GJ^#, Chen TB, Joseph D, Tao WK, Vanko A, Connolly B, David L. Williams J, Cyrille S. Visualization of mitotic arrest of cell cycle with bioluminescence imaging in living animals. Molecular Imaging and Biology. 2013 Aug;15(4):431-40.

93. Chen M, Cui YK, Huang WH, Man K, Zhang GJ^#. Phosphorylation of estrogen receptor α at serine 118 is correlated with breast cancer resistance to tamoxifen. Oncology Letters. 2013 Jul;6(1):118-124.

94. Xu HW, Huang YJ, Xie ZY^#, Lin L, Guo YC, Zhuang ZR, Lin XP, Zhou W, Mu L, Huang HH, Wei XL, Man K, Zhang GJ^#. The expression of cytoglobin as a prognostic factor in gliomas:a retrospective analysis of 88 patients. BMC Cancer. 2013 May 20; 13:247.

95. Chen HW, Du CW, Wei XL, US Khoo, Zhang GJ^#. Cytoplasmic CXCR4 high-expression exhibits distinct poor clinicopathological characteristics and predicts poor prognosis in triple-negative breast cancers. Current Molecular Medicine. 2013 Mar;13(3):410-6.

96. Chen ZH, Zhao RJ, Li RH, Guo CP, Zhang GJ^#. Bioluminescence imaging of DNA synthetic phase of cell cycle in living animals. PLoS One. 2013; 8(1): e53291.

97. Liu J, Wei XL, Huang WH, Chen CF, Bai JW, Zhang GJ^#. Cytoplasmic Skp2 expression is associated with p-Akt1and predicts poor prognosis in human breast carcinomas. PLoS One. 2012;7(12): e52675.

98. Du CW, Kimijima I, Otake T, Abe R, Takenoshita S, Zhang GJ^#. Down-regulation of p73 correlates with high histological grade in Japanese with breast carcinomas. Chinese Medical Journal. 2011 Aug;124(15):2275-8.

99. Zhang GJ^#, Chen TB, Connolly B, Lin SA, Hargreaves R, Vanko A, Bednar B, MacNeil DJ, Sur C, Williams DL^#. In vivo optical imaging of LacZ expression using lacZ transgenic mice. Assay and Drug Development Technologies. 2009 Aug;7(4):391-9.

100. Zhang GJ^#, Chen TB, Hargreaves R, Sur C, Williams Jr DL. Bioluminescence imaging of hollow fibers in living animals: its application in monitoring molecular pathways. Nature Protocols. 2008;3(5):891-9.

101. Zhang GJ^#, Chen TB, Bednar B, Connolly BM, Hargreaves R, Sur C, Williams Jr DL. Optical imaging of tumor cells in hollow fibers: evaluation of the antitumor activities of anticancer drugs and target validation. Neoplasia. 2007 Aug;9(8):652-61.

102. Zhang GJ^#, Kaelin Jr WG. Bioluminescent imaging of ubiquitin ligase activity: measuring Cdk2 activity in vivo through changes in p27 turnover. Methods in Enzymology. 2005; 399:530-49.

103. Zhang GJ, Safran M, Wei W, Sorensen E, Lassota P, Shapiro G, Zhelev N, Kaelin Jr WG^#. Bioluminescent imaging of CDK2 inhibition in vivo. Nature Medicine. 2004 Jun;10(6):643-8.

104. Zhang GJ^#, Kimijima I, Fukushima T, Sato H, Kanno M, Tsuchiya A, Abe R. Tamoxifen-induced apoptosis in breast cancer cells relates to down-regulation of bcl-2, but not bax and bcl-XL, without alteration of p53 protein levels. Clinical Cancer Research. 1999 Oct;5(10):2971-7.

105. Zhang GJ^#, Adachi I. Serum levels of soluble intercellular adhesion amolecule-1 and E-Selectin in metastatic breast carcinomas: correlations with Clinicopathological features and prognosis. International Journal of Oncology. 1999 Jan;14(1):71-7.

106. Zhang GJ^#, Kimijima I, Tsuchiya A, Abe R. The role of bcl-2 expression in breast carcinomas (Review). Oncology Reports. 1998 Sep-Oct;5(5):1211-6.

107. Zhang GJ^#, Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Research. 1999 Mar-Apr;19(2B):1427-32.

108. Zhang GJ^#, Kimijima I, Abe R, Watanabe T, Kanno M, Hara K, Tsuchiya A. Apoptotic index correlates to bcl-2 and p53 protein expression, histological grade and prognosis in invasive breast cancers. Anticancer Research. 1998 May-Jun;18(3B):1989-98.

109. Zhang GJ^#, Tsuda H, Adachi I, Fukutomi T, Yamamoto H, Hirohashi S. Prognostic indicators for breast cancer patients with one to three regional lymph node metastases, with special reference to alterations in expression levels of bcl-2, p53 and c-erbB-2 proteins. Japanese Journal of Clinical Oncology. 1997 Dec;27(6):371-7.

110. Zhang GJ^#, Adachi I, Duan Z, Zhang Q, Guo R, Tang L, Gong C, He S. The accuracy of color doppler flow imaging for the detection of symptomatic deep venous thrombosis in Chinese patients. Surgery Today (Japanese Journal of Surgery). 1996;26(9):683-7.

111. Zhang GJ^#, Adachi I, Yin DF, Narabayashi M, Tokue Y, Watanabe T, Kaneko A, Tsuda H, Abe K. Eyelid metastasis from breast cancer showing marked response to chemotherapy. Japanese Journal of Clinical Oncology. 1995 Feb;25(1):10-5.

112. Zhang GJ^#, Adachi I, Okamoto R, Watanabe T, Narabayashi M, Tokue Y, Katsumata M. Tumor-associated fever in recurrent breast cancer with liver metastases. Breast Cancer. 1994 Dec 30;1(2):145-150.

113. 陈伟玲; 张国君^#; 乳腺癌术前治疗中外指南对比解读中国肿瘤外科杂志114. 李良涛，牛蕾，朱江雯，黄文河，张国君^#. 原发性甲状旁腺功能亢进症的诊断和治疗进展国际外科学杂志115. 陈敏，林琳玲，何悦洋，杜智铖，张国君^#. 光学分子影像技术在药物疗效评估和乳腺癌外科手术导航中的应用进展厦门大学学报自然科学版116. 戚玉竹，刘静^#，张国君^#. 核苷酸酶在恶性肿瘤中作用和调控机制的研究进展癌变畸变突变117. 袁颖，张国君^#，黄文河. 乳房植入体相关性间变性大细胞淋巴瘤的诊疗策略肿瘤学杂志118. 陈伟玲，张永渠，李瑶琛，Min Chen，黄文河，张国君^#. Notch和信号通路及两者的交叉串话与乳腺癌发生、发展的关系中华乳腺病杂志119. 李少钟，刘静^#，张国君^#. PARP抑制剂在胚系突变乳腺癌治疗中作用的研究进展中国普外基础与临床杂志120. 叶娴，郭翠萍，张国君^#. 基于全基因组关联研究的乳腺癌预后预测研究现状中华乳腺病杂志121. 沈家欣，刘静，陈鸿雁，张国君^#. RNA干扰高通量筛选技术在乳腺癌研究领域的应用中华实验外科杂志122. 温晓芬，许宏武，Min Chen，张国君^#. 分化抑制因子的生物学功能及其在乳腺癌中的研究进展中华乳腺病杂志123. 贺丽芳，黄文河，张国君^#. 恶性肿瘤的光学分子影像手术导航中国肿瘤临床124. 曾焕城，邱斯奇，黄文河，张国君^#. 乳腺癌患者腋窝淋巴结转移状态的预测国际肿瘤学杂志125. 罗香蓉，魏晓龙，陈伟玲，张国君^#. 叉头盒蛋白在乳腺癌的作用国际肿瘤学杂志126. 黄文河，吴俊东，张国君^#，吴碧娟，陈明，黄子一，杜彩文. 不可手术局部晚期乳腺癌的多学科综合治疗西部医学127. 席迪迪，温晓芬，张国君^#. Kruppel样因子的研究进展及其在乳腺癌中的意义中华乳腺病杂志128. 冼志荣，张国君^#. 多柔比星的耐药机制国际肿瘤学杂志129. 白静雯，黄文，张国君^#. Snail 家族指蛋白与雌激素受体的关系在乳腺癌中的研究进展中华内分泌外科杂志130. 张永渠，豆晓伟，张国君^#. Notch信号转导通路与乳腺癌靶向治疗国际肿瘤学杂志131. 韦锦涛，黄文河，张国君^#. 年轻乳腺癌的临床病理学特征与治疗策略中华乳腺病杂志132. 李荣晖，杜彩文，黄文河，张国君^#. 从合成致死策略谈三阴性乳腺癌的靶向治疗中国肿瘤临床133. 陈春发，豆晓伟，张国君^#. Notch3的表达与乳腺癌发生发展的关系中华乳腺病杂志134. 何德，张国君^#. 肥胖与乳腺癌关系的研究进展中华乳腺病杂志135. 李荣晖，杜彩文，张国君^#. 三阴性乳腺癌的靶向治疗研究进展国际肿瘤学杂志136. 丁浩龙，张国君^#. 光学分子影像技术在转基因动物模型中的应用研究中华核医学与分子影像杂志137. 郭翠萍，张国君^#. 细胞周期蛋白的调控与恶性肿瘤国际肿瘤学杂志138. 王静巍，黄文河，张国君^#. 在体光学分子影像技术在乳腺癌基础及临床研究中的应用中华核医学与分子影像杂志139. 贺丽芳，张国君^#. P21活化激酶４与肿瘤的研究进展国际肿瘤学杂志140. 黄崇植，张国君^#. 家族性乳腺癌研究现状中国实用外科杂志141. 刘静，张国君^#. 光学分子影像技术及其在药物研发领域的应用生物物理学报142. 赵瑞君，张国君^#. 光学分子影像技术在抗肿瘤药物研发中的应用国际肿瘤学杂志143. 吴俊东，黄文河，陈明，魏晓龙，马长春，张国君^#. 三阴性乳腺癌与过表达乳腺癌患者的临床病理特征及预后比较中华内分泌外科杂志144. 吴俊东，黄文河，庄业忠，王伟峰，陈明，张国君^#. 淋巴管结扎联合医用胶预防乳腺癌术后皮下积液分析实用癌症杂志145. 陈宏武，吴国英，张国君^#. CXCR4表达对乳腺癌进展及预后的意义国际肿瘤学杂志146. 李仰康，张国君^#，周修国. 钼靶线检查在乳腺癌保乳手术中的应用国际肿瘤学杂志147. 杜彩文，张国君^#. 三阴性乳腺癌的临床特点与治疗国际肿瘤学杂志148. 杜彩文，陈宏武，黄文河，张国君^#，洪超群，陈炯玉，魏晓龙，马长春. 三阴性乳腺癌患者的临床特点及预后分析中国现代医药杂志149. 安达勇，张国君^#. 乳腺癌内分泌药物治疗的现状与问题日本医学介绍150. 徐显春，张国君^#. 成人肠套叠例诊治分析中国医科大学学报，151. Zhang GJ, Duan Z, Zhang Q. Diagnosis and Treatment of Traumatic aneurysm, report of 21 cases. Chinese Practical Journal of Surgery, 1992 supplement, 332. (in Chinese)

152. Zhang GJ, Duan Z, Liu Z, Dong Y. Treatment of ARDS patients following abdominal surgery with ventilator. Chinese Practical Journal of Surgery, 1991 supplement, 77-9. (in Chinese)

153. 张国君^#. 前列腺癌治疗中的问题日本医学介绍 

著作

1. 《乳腺癌生物标志物检测临床应用指南》. 中华病理学杂志. 2025.10. 参编

2. 《乳腺癌分子病理检测临床实践指南》.中华肿瘤杂志. 2025.10. 参编

3. 《晚期乳腺癌基因检测临床应用指南》. 中华肿瘤杂志. 2025.10. 参编

4. 《中国抗癌协会乳腺癌诊治指南与规范（2026年版）》. 中国癌症杂志. 2025. 参编

5. 《全专结合全方位管理乳腺癌伴随疾病中国专家共识》. 中华内分泌外科杂志. 2025. 参编

6. 《女性乳腺癌患者代谢相关脂肪性肝病管理中国专家共识（2025版）》. 中华内分泌外科杂志. 2025. 参编

7. 《中国乳腺癌患者BRCA1/2基因检测与临床应用专家共识（年版）》. 中国癌症杂志. 2025.7.30. 参编

8. 《七成乳腺癌复发风险管理专家共识》中华肿瘤杂志参编

9. Application of Near-infrared Fluorescence Imaging in Cancer SurgerySpringer Singapore10. 《与肿瘤面对面:48例肿瘤患者的治疗经历及专家科普》.中国人口与健康出版社.2025.03.01.主编

11. 《肿瘤学（第三版）》，国家卫生健康委员会“十四五”规划教材，人民卫生出版社参编

12. 《乳腺癌保乳治疗与切缘精准评估技术》，清华大学出版社. 2023. 主编

13. 《乳腺癌前哨淋巴结活检规范化操作指南（2022精要版）》中国肿瘤临床编委

14. 《晚期乳腺癌基因检测热点问题中国专家共识(2021版》参编

15. 《腹膜后肿瘤三维可视化精准诊治专家共识（2018版）》中国实用外科杂志参编16. 《计算机辅助联合吲哚菁绿分子荧光影像技术在肝脏肿瘤诊断和手术导航中的应用专家共识》. 中国实用外科杂志参编17. 《肿瘤学（第五版）》，国家卫生健康委员会十三五规划教材，人民卫生出版社，编委18. 《临床分子影像检测技术》，人民卫生出版社，2019. 编委19. 《Oncology（英文版）》，国家卫生和计划生育委员会“十三五”英文版规划教材，人民卫生出版社，2018. 副主编20. 《乳腺癌》译作，人民卫生出版社，2011.12.21. 主译 出版号 9787117144179. 总字数(字910000. 本人撰写字数(字910000.

21. 《肿瘤学》，卫生部十一五研究生规划教材，人民卫生出版社，编者 出版号978-7-117-13120-9. 总字数(字765000. 本人撰写字数(字5400.

22. Bai JW, Zhang YQ, Li YC, Zhang GJ. Analysis of Epithelial-Mesenchymal Transition Induced by Overexpression of Twist. Chapter 17, ErbB Receptor Signaling: Methods and Protocols, Methods in Molecular Biology, 2017,1652: 259-74.

23. Bednar B, Zhang GJ, Sur C, "Anticancer Drug Development with Optical Imaging" in "Molecular Imaging in Oncology" (Editors: Martin Pomper & Juri Gelovani), Informa Healthcare, New York, 2008, p645-58.

24. Zhang GJ, Kaelin WG Jr. Cancer genetisc and drug target selection. Molecular Cancer Therapeutics (Editor: Prendergast GC), Strategies for Drug Discovery and Development, 2004, P42-51. (ISSN: 1535-7163)

专利

1. 一种辅助固定麻醉鼠成像的小鼠恒稳仪（实用新型专利；专利号：；发明人：张国君、陈俊宏、陈伟玲、朱媛媛）

2. 一种镧系稀土纳米探针及其制备方法和应用（发明专利；专利号：；发明人：张国君、明梓何、宋良、张永渠、黄文河、白静雯、林琳玲、何悦洋）

3. 一种Ⅱ发射的稀土纳米探针及其制备方法和应用（发明专利；专利号：；发明人：张国君、刘小龙、党永颖、王培园、白静雯、楼康良、黄文河）

4. 一种用于肿瘤 Ⅱ荧光成像及放疗增敏免疫联合治疗的可降解分子探针及应用（发明专利；专利号：；发明人：张国君、何悦洋、李阳、白静雯、曹艳兵、沈筱）

5. 一种靶向 的近红外二区荧光探针及其制备方法和应用（发明专利；专利号：；发明人：张国君、陈伟玲、张莉欣、张永渠、朱媛媛、黄文河、王佳铮）

6. 一种引导乳腺癌保乳切缘精准评估的荧光/核磁探针（发明专利；专利号：；发明人：张国君、张永渠、刘婉玲、Min Chen、罗祥杰、黄文河）

7. 一种用于无创评估乳腺癌前哨淋巴结转移的靶向分子探针（发明专利；专利号：ZL 202210234060.4 ；发明人：张国君、朱媛媛、宋良、张永渠）

8. 一种用于乳腺癌NIR-II区荧光手术导航及放疗增敏的靶向分子探针（发明专利；专利号：；发明人：张国君、魏敏、王培园、白静雯、黄文河、高艺洋）

9. 活体内检测CK4/6激酶活性的分子探针及其应用（发明专利；专利号：ZL 2021 1 1294233.3；发明人：张国君、高艺洋、杨瑞钦、董媛媛、Min Chen、楼康良）

10. 基于超声医学的乳腺结节检测方法及系统（发明专利；专利号：ZL202010924386.0；发明人：张国君、李卫斌、陈敏、王连生、陈云超、徐辉雄）

11. 一种用于引导肿瘤切除的光声成像手术导航平台（发明专利；专利号：ZL202010645805.7；发明人：张国君、王尊、陈敏、聂立铭、黄珊珊、李宏辉）

12. 赵旭晔、张国君、黄文河、康欣梅、牛蕾、李良涛（实用新型；专利号：ZL202021711459.X；发明人：赵旭晔、张国君、黄文河、康欣梅、牛蕾、李良涛）

13. hTERT-miR-221/222海绵及其在逆转乳腺癌的他莫昔芬耐药中的应用（发明专利；专利号：；发明人：张国君、陈敏、欧阳檐秀、冯军）

14. 细胞周期S期报告基因（发明专利；专利号：；发明人：张国君、赵瑞君、陈志鸿）

获奖

1. 中华医学会乳腺肿瘤学组 “年度乳腺领域十大原创研究”项目名称：乳腺癌术中肿瘤切缘精准评估分子影像技术；完成人：张国君，陈伟玲，张莉欣，张永渠，朱媛媛，黄文河，王佳铮2. 2021年度福建省科学技术进步奖三等奖（项目名称：创新光学分子影像技术体系的建立及其在乳腺癌精准外科的应用；完成人：张国君，黄文河，白静雯，邱斯奇，曾焕城）

3. 厦门市2020-2021年度十大医疗创新技术（项目名称：乳腺癌精准外科中分子影像技术的创新研究与应用；完成人：张国君，黄文河，白静雯，陈伟玲等）

4. 2020年度中国抗癌协会科技奖二等奖（项目名称：分子影像导引的乳腺癌诊疗一体化研究及临床应用；完成人：张国君，迟崇巍，王殊，Min Chen，杜彩文，白静雯，梁元科）

5. 2020年厦门市科学技术进步奖二等奖（项目名称：可视化分子影像技术在乳腺癌精准外科的基础研究与临床应用；完成人：张国君，刘静，迟崇巍，黄文河，杜彩文，白静雯，陈志鸿，李荣晖）

6. 2019年度辽宁省科学技术进步奖二等奖（项目名称：乳腺癌多学科综合治疗策略的建立与应用；完成人：滕月娥，郭志刚，张国君，刘云鹏，徐璐，陈波，米小轶，张立娜，石晶）

7. 2016年度广东省科学技术奖三等奖（项目名称：乳腺癌转移进展机制及预后研究；完成人：张国君，杜彩文，刘静，崔玉坤，黄文河，魏晓龙，陈宏武）

8. 第九届潮汕星河国瑞科技奖（完成人：张国君）

9. 2014年度汕头市科技进步奖一等奖（项目名称：乳腺癌转移进展机制及预后研究；完成人：张国君，杜彩文，刘静，崔玉坤，黄文河，魏晓龙，陈宏武，许宏武，马长春）